GW Pharma is the clear worldwide leader in cannabis-based pharmaceuticals
- GW’s pipeline has a number of significant treatments in development for epilepsy, glioma and schizophrenia.
- Results for its lead candidate Epidiolex in LGS and Dravet syndrome appear quite promising and definitive.
- The company appears to have an event-filled second half of the year and early 2018 with several opportunities for value creation.
GW Pharma (GWPH) is a regular biotech company that is developing therapies for regular diseases using a very irregular and unusual therapeutic base - cannabinoids. That gives it a clear edge in a sea of fly-by-night mom-and-pop joints which have come up after the United States decided to take a hands-off approach towards the medical and recreational marijuana industry. Many of these other companies have been multibaggers, going up and sometimes down in a frenzy of (marijuana) excitement. However, GWPH is a serious company, and its aim is to discover if there’s any truth behind the millennia-old belief in the medicinal properties of marijuana. At least that is how I look at this investment.
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.